Christina Kehl Cramer

Christina Kehl Cramer

Auto-generated profile, based on publicly available information

Christina Kehl Cramer

Department of Radiation Oncology, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 April 2019 in Current Treatment Options in Oncology
Verified
Journal Article
Closed access
PDF file
CCChristina K. Cramer
Christina K. Cramer
TCTiffany L. Cummings
Tiffany L. Cummings
RARachel N. Andrews
Rachel N. Andrews
RSRoy Strowd
Roy Strowd
SRStephen R. Rapp
Stephen R. Rapp
GLGlenn J. Lesser
Glenn J. Lesser

7 November 2018 in Journal of Neuro-Oncology
Verified
Journal Article
Closed access
PDF file
CCChristina K. Cramer
Christina K. Cramer
NMNeil McKee
Neil McKee
LCL. Doug Case
L. Doug Case
MCMichael D. Chan
Michael D. Chan
TCTiffany L. Cummings
Tiffany L. Cummings
SRStephen R. Rapp
Stephen R. Rapp

12 November 2018 in Journal of Cancer Research and Clinical Oncology
Verified
Journal Article
Closed access
PDF file
CCChristina K. Cramer
Christina K. Cramer
NANatalie Alphonse-Sullivan
Natalie Alphonse-Sullivan
SIScott Isom
Scott Isom
LMLinda J. Metheny-Barlow
Linda J. Metheny-Barlow
TCTiffany L. Cummings
Tiffany L. Cummings
MCMichael D. Chan
Michael D. Chan

28 November 2021 in Cureus
Verified
Journal Article
Open access
CLClaire M. Lanier
Claire M. Lanier
MLMichael Lecompte
Michael Lecompte
CGChase Glenn
Chase Glenn
RHRyan T Hughes
Ryan T Hughes
SIScott Isom
Scott Isom
ALAdrian Laxton
Adrian Laxton
Laser-interstitial thermal therapy (LITT) has been proposed as an alternative treatment to surgery for radiation necrosis (RN) in patients treated with stereotactic radiosurgery (SRS) for brain metastases. The present study sought to retrospectively analyze LITT outcomes in patients with RN from SRS. This was a single-institution retrospective study of 30 patients treated from 2011-2018 with pathologically-proven RN after SRS for brain metastases (n=28) or proximally treated extracranial lesions treated with external beam radiotherapy (n=2). Same-day biopsy was performed in all cases. Patients were prospectively followed with Functional Assessment of Cancer Therapy - Brain (FACT-Br), EuroQol-5 Dimension (EQ-5D), Hopkins Verbal Learning Test (HVLT) and clinical history and examination. Adjusted means, standard errors and tests comparing visits to pre-LITT were generated. Kaplan-Meier method was used to estimate time overall survival. Competing risk analysis was used to estimate cumulative incidence of LITT failure. In our patient population, median time from radiotherapy to LITT was 13.1 months. Median SRS dose and median LITT treatment target volume were 20 Gy (IQR 18-22) and 3.5 cc (IQR 2.2-4.6), respectively. Seventy-seven percent of our patients tapered off steroids within one month. There were only two instances of RN recurrence after LITT, with recurrence defined as recurrence of symptoms after initial improvement. These recurrences occurred at 1.9 and 3.4 months. The three-, six- and nine-month freedom from recurrence rates were 95.7%, 90.9%, and 90.9%. Median survival in our patient population with pathologically confirmed RN treated with LITT was 2.1 years. Regarding the quality of life questionnaires with which some patients were followed as part of different prospective studies, completion rates were 22/30 for FACT-Br, 16/30 for the EQ-5D and 8/30 for HVLT. Quality of life questionnaire results were overall stable from baseline. Mean FACT-Br scores were stable from baseline (17.9, 16.6, 21.4 and 22.8) to three months (18.8, 15.4, 18.4 and 23.4) (p=0.38, 0.53, 0.09 and 0.59). The mean EQ-5D Aggregate score was stable from baseline (7.1) to one month (7.6) (p=0.25). Mean HVLT-R Total Recall was stable from baseline (20.6) to three months (18.4) (p=0.09). There was a statistically significant decrease in mean Karnofsky Performance Scale (KPS) score from baseline (84) to three-month follow-up (75) (p=0.03). LITT represents a safe and durably effective treatment option for RN in the brain. Results demonstrate a median survival of 2.1 years from LITT with only two recurrences, both within four months of treatment and salvageable. Patient-reported outcomes showed no severe declines after LITT. Quality of life questionnaires demonstrated stable well-being and functionality from baseline. LITT should be considered for definitive treatment of RN, especially in cases where patients have significant side effects from standards medical therapies such as steroids or if steroids are minimally effective.

13 June 2025 in Cancers
Verified
Journal Article
Open access
PDF file
YCYijun Chen
Yijun Chen
CHCorbin A. Andrew Helis
Corbin A. Andrew Helis
CCChristina Cramer
Christina Cramer
MMMichael T. Munley
Michael T. Munley
CCChoi Choi
Choi Choi
YJYuming Jiang
Yuming Jiang
Background: Radiation therapy is a primary and cornerstone treatment modality for brain metastasis. However, it can result in complications like necrosis, which may lead to significant neurological deficits. This study aims to develop and validate an ensemble model with radiomics to predict radiation necrosis. Method: This study retrospectively collected and analyzed MRI images and clinical information from 209 stereotactic radiosurgery sessions involving 130 patients with brain metastasis. An ensemble model integrating gradient boosting, random forest, decision tree, and support vector machine was developed and validated using selected radiomic features and clinical factors to predict the likelihood of necrosis. The model performance was evaluated and compared with other machine learning algorithms using metrics, including the area under the curve (AUC), sensitivity, specificity, negative predictive value (NPV), and positive predictive value (PPV). SHapley Additive exPlanations (SHAP) analysis and local interpretable model-agnostic explanations (LIME) analysis were applied to explain the model’s prediction. Results: The ensemble model achieved strong performance in the validation cohort, with the highest AUC. Compared to individual models and the stacking ensemble model, it consistently outperformed. The model demonstrated superior accuracy, generalizability, and reliability in predicting radiation necrosis. SHAP and LIME were used to interpret a complex predictive model for radiation necrosis. Both analyses highlighted similar significant factors, enhancing our understanding of prediction dynamics. Conclusions: The ensemble model using radiomic features exhibited high accuracy and robustness in predicting the occurrence of radiation necrosis. It could serve as a novel and valuable tool to facilitate radiotherapy for patients with brain metastasis.